Product Misk

Product

Product Catalog

Our product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory medicine, neurology and gastroenterology. We focus on niche generics, transdermal patches, controlled release, and first to file and first to market products.

OTC Portfolio

Misk Pharma offers an innovative OTC portfolio, covering food supplements, OTC medicines, cosmetics, and medical devices. We focus on patented technologies, clinically proven formulations, and health care portfolio like pain relievers, antihistamines, and digestive aids.

Our strategy centers on market-driven innovation, enhancing products with superior ingredient compositions, advanced delivery forms, and improved consumer experience. With a commitment to quality, efficacy, and accessibility, Misk Pharma delivers smart self-care solutions for everyday health.

Generics Portfolio

Misk Pharma’s generics business is built on a strong foundation of expertise and innovation, ensuring high-quality, cost-effective alternatives to branded medications. Our experienced team has developed a robust and profitable infrastructure, enabling us to compete in key markets.

Our diverse portfolio includes solid oral doses, modified-release tablets, soft gelatin capsules, oral suspensions, injectables (pen and vial). With a focus on efficacy, affordability, and global regulatory compliance, we provide trusted solutions that enhance patient access to essential medicines

Branded Portfolio

Misk Pharma is dedicated to the acquisition, development, and commercialization of high-quality branded pharmaceuticals. Our portfolio includes innovative therapies in pain management, anti-infectives, cardiovascular care, and psychiatry.

With strong in-house expertise and a global network of partners, our business model ensures speed, flexibility, and a competitive edge in bringing advanced treatments to market. Through continuous innovation, we strive to improve patient outcomes and expand access to high-value medications